文献速递血栓与止血

荷兰血友病患者健康与治疗结局:1972-2019年

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019.
PubMed 文献 · J Thromb Haemost · 2021-07-07

该研究通过六次全国性横断面问卷调查,评估1972至2019年荷兰血友病患者健康结局变化,重点关注50岁以上患者。结果显示重型血友病预防治疗使用率从30%升至89%,中位年出血率从25次降至2次,丙肝活跃感染从45%降至2%,但40岁以上患者关节状况未改善,50岁以上患者生活质量显著低于一般男性人群。

要点

  • 重型血友病预防治疗使用率从30%升至89%,中位年出血率从25次降至2次。
  • 丙肝活跃感染比例从2001年45%降至2019年2%,但25%患者仍有显著肝纤维化。
  • 40岁以上患者关节状况未改善,50岁以上患者RAND-36评分显著低于一般男性人群。

核心结论

  • 预防治疗增加和有效丙肝治疗改善了荷兰血友病患者关节健康并近乎消除丙肝感染。
  • 患者仍存在血友病相关并发症,尤其是50岁以上患者。

研究设计与样本

  • 六次全国性横断面问卷研究,覆盖1972至2019年荷兰所有血友病患者。
  • 2019年共1009例患者参与,其中轻型48%、中型15%、重型37%。

主要发现

  • 重型血友病预防治疗使用率从1972年30%升至2019年89%。
  • 重型血友病中位年出血率从25次降至2次。
  • 2019年全部1009例患者中5%HIV阳性。
  • 丙肝活跃感染比例从2001年45%降至2019年2%,但25%患者成功治疗后仍有显著肝纤维化。
  • 50岁以上患者RAND-36评分显著低于一般男性人群,尤其躯体功能。

临床怎么用

  • 应持续推广重型血友病预防治疗以降低出血率。
  • 应重视丙肝治疗后肝纤维化的长期监测。
  • 对50岁以上血友病患者需关注生活质量和躯体功能下降。

局限性

  • 为横断面问卷研究,无法确立因果关系。
  • 仅纳入荷兰患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We conducted six cross-sectional nationwide questionnaire studies among all patients with hemophilia in the Netherlands from 1972 until 2019 to assess how health outcomes have changed, with a special focus on patients >50 years of age. METHODS: Data were collected on patient characteristics, treatment, (joint) bleeding, joint impairment, hospitalizations, human immunodeficiency virus and hepatitis C infections, and general health status (RAND-36). RESULTS: In 2019, 1009 patients participated, of whom 48% had mild, 15% moderate, and 37% severe hemophilia. From 1972 to 2019, the use of prophylaxis among patients with severe hemophilia increased from 30% to 89%. Their median annual bleeding rate decreased from 25 to 2 bleeds. Patients with severe hemophilia aged <16 years reported joint impairment less often over time, but in those aged >40 years joint status did not improve. In 2019, 5% of all 1009 patients were positive for the human immunodeficiency virus. The proportion of patients with an active hepatitis C infection drastically decreased from 45% in 2001 to 2% in 2019 due to new anti-hepatitis C treatment options. Twenty-five percent had significant liver fibrosis even after successful therapy. Compared to the general male population, patients aged >50 years reported much lower scores on the RAND-36, especially on physical functioning. DISCUSSION/CONCLUSION: Our study shows that increased use of prophylactic treatment and effective hepatitis C treatment have improved joint health and nearly eradicated hepatitis C infection in patients with hemophilia in the Netherlands. However, patients still suffer from hemophilia-related complications, especially patients aged >50 years.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hassan S, van Balen EC, Smit C, et al. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019. J Thromb Haemost. 2021. PMID: 34117710. doi:10.1111/jth.15424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。